DK170670B1 - Kondenserede diazepinoner, fremgangsmåde til deresfremstilling, lægemidler indeholdende en sådan diazepinon, samt anvendelse af sådanne diazepinoner til fremstilling af lægemidler - Google Patents
Kondenserede diazepinoner, fremgangsmåde til deresfremstilling, lægemidler indeholdende en sådan diazepinon, samt anvendelse af sådanne diazepinoner til fremstilling af lægemidler Download PDFInfo
- Publication number
- DK170670B1 DK170670B1 DK669187A DK669187A DK170670B1 DK 170670 B1 DK170670 B1 DK 170670B1 DK 669187 A DK669187 A DK 669187A DK 669187 A DK669187 A DK 669187A DK 170670 B1 DK170670 B1 DK 170670B1
- Authority
- DK
- Denmark
- Prior art keywords
- piperidinyl
- methyl
- dihydro
- ethyl
- pyrido
- Prior art date
Links
- DHZYXWMZLAKTQV-UHFFFAOYSA-N diazepin-3-one Chemical class O=C1C=CC=CN=N1 DHZYXWMZLAKTQV-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims description 24
- 239000003814 drug Substances 0.000 title claims description 9
- 230000008569 process Effects 0.000 title claims description 8
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title description 11
- 229940079593 drug Drugs 0.000 title description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 157
- 150000001875 compounds Chemical class 0.000 claims abstract description 101
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 18
- 239000001257 hydrogen Substances 0.000 claims abstract description 17
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 14
- 239000000460 chlorine Chemical group 0.000 claims abstract description 13
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 12
- 208000006218 bradycardia Diseases 0.000 claims abstract description 9
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 8
- 230000036471 bradycardia Effects 0.000 claims abstract description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 6
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 153
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 144
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 143
- -1 5, 10-Dihydro-5 - [[[2- [2 - [(dimethylamino) methyl] -1-piperidinyl] ethyl] amino] carbonyl] -1H-dibenzo [b, e ] [1,4] diazepin-11-one Chemical compound 0.000 claims description 107
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 99
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 36
- 238000006243 chemical reaction Methods 0.000 claims description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 28
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 claims description 27
- 239000002904 solvent Substances 0.000 claims description 27
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 238000009835 boiling Methods 0.000 claims description 11
- 125000003386 piperidinyl group Chemical group 0.000 claims description 10
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 9
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 9
- 239000011541 reaction mixture Substances 0.000 claims description 9
- 150000007522 mineralic acids Chemical class 0.000 claims description 8
- 150000007524 organic acids Chemical class 0.000 claims description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 7
- 235000005985 organic acids Nutrition 0.000 claims description 7
- 150000007530 organic bases Chemical class 0.000 claims description 7
- 239000007858 starting material Substances 0.000 claims description 7
- 239000002585 base Substances 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 5
- 239000003054 catalyst Substances 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 150000004985 diamines Chemical class 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- 150000001340 alkali metals Chemical group 0.000 claims description 4
- 150000001342 alkaline earth metals Chemical group 0.000 claims description 4
- 239000012442 inert solvent Substances 0.000 claims description 4
- 150000007529 inorganic bases Chemical class 0.000 claims description 4
- PJUPMXXMRDMORI-UHFFFAOYSA-N 9-chloro-n-[2-[2-(diethylaminomethyl)piperidin-1-yl]ethyl]-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound CCN(CC)CC1CCCCN1CCNC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=C(Cl)C=C21 PJUPMXXMRDMORI-UHFFFAOYSA-N 0.000 claims description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical group ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 239000012948 isocyanate Substances 0.000 claims description 3
- 150000002513 isocyanates Chemical class 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 230000000737 periodic effect Effects 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 239000002798 polar solvent Substances 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- HCDXLUKTYFLIEM-UHFFFAOYSA-N 1,2-benzodiazepin-5-one Chemical compound O=C1C=CN=NC2=CC=CC=C12 HCDXLUKTYFLIEM-UHFFFAOYSA-N 0.000 claims description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 150000002736 metal compounds Chemical class 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims 2
- GILSTWNXNNVASG-UHFFFAOYSA-N 4-[[[2-[2-[(diethylamino)methyl]-piperidin-1-yl]ethyl]amino]carbonyl]-1,3-dimethyl-1,4,9,10-tetrahydropyrazolo[4,3-e]pyrido[2,3-b][1,4]diazepin-10-one Chemical compound CCN(CC)CC1CCCCN1CCNC(=O)N1C2=CC=CN=C2NC(=O)C2=C1C(C)=NN2C GILSTWNXNNVASG-UHFFFAOYSA-N 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 239000012038 nucleophile Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 8
- 230000001515 vagal effect Effects 0.000 abstract description 5
- 229910052736 halogen Inorganic materials 0.000 abstract description 4
- 150000002367 halogens Chemical class 0.000 abstract description 4
- 229910052717 sulfur Inorganic materials 0.000 abstract description 2
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- 206010049765 Bradyarrhythmia Diseases 0.000 abstract 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical group FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 abstract 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 271
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 168
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 141
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 132
- 239000013078 crystal Substances 0.000 description 109
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 75
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 67
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 46
- KSSXNHGPIDAUAS-UHFFFAOYSA-N 1,4-benzodiazepin-6-one Chemical compound N1=CC=NC=C2C(=O)C=CC=C21 KSSXNHGPIDAUAS-UHFFFAOYSA-N 0.000 description 44
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- 239000003480 eluent Substances 0.000 description 40
- 239000002985 plastic film Substances 0.000 description 36
- 229910021529 ammonia Inorganic materials 0.000 description 35
- 239000000203 mixture Substances 0.000 description 35
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 34
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 33
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 29
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Natural products CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- WTQIDDAZNKRWMF-UHFFFAOYSA-N 6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carbonyl chloride Chemical compound O=C1NC2=CC=CN=C2N(C(=O)Cl)C2=CC=CC=C21 WTQIDDAZNKRWMF-UHFFFAOYSA-N 0.000 description 25
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 25
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 23
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 20
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 20
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 19
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- YZPAKBGVJIVPEU-UHFFFAOYSA-N 1,2-benzodiazepin-6-one Chemical compound N1=NC=CC=C2C(=O)C=CC=C21 YZPAKBGVJIVPEU-UHFFFAOYSA-N 0.000 description 14
- UJWQYKYQDVBFTA-UHFFFAOYSA-N 2-[2-(diethylaminomethyl)piperidin-1-yl]ethanamine Chemical compound CCN(CC)CC1CCCCN1CCN UJWQYKYQDVBFTA-UHFFFAOYSA-N 0.000 description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 14
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 14
- 239000012230 colorless oil Substances 0.000 description 13
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 11
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
- 239000013543 active substance Substances 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 125000001309 chloro group Chemical group Cl* 0.000 description 9
- 229960004592 isopropanol Drugs 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- BDUOLKYQDXVZFM-UHFFFAOYSA-N 9-chloro-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carbonyl chloride Chemical compound O=C1NC2=CC=CN=C2N(C(=O)Cl)C2=CC(Cl)=CC=C21 BDUOLKYQDXVZFM-UHFFFAOYSA-N 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 8
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 8
- 229910052741 iridium Inorganic materials 0.000 description 8
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 229910052794 bromium Inorganic materials 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 7
- 150000003335 secondary amines Chemical class 0.000 description 7
- 239000000829 suppository Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- 239000007868 Raney catalyst Substances 0.000 description 6
- 229910000564 Raney nickel Inorganic materials 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 239000008096 xylene Substances 0.000 description 6
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 5
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 5
- OWVGZRGQBRCQCZ-UHFFFAOYSA-N 2-[2-(diethylaminomethyl)piperidin-1-yl]acetonitrile Chemical compound CCN(CC)CC1CCCCN1CC#N OWVGZRGQBRCQCZ-UHFFFAOYSA-N 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 5
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 5
- 230000001022 anti-muscarinic effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 150000002170 ethers Chemical class 0.000 description 5
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 5
- 239000012280 lithium aluminium hydride Substances 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 125000005999 2-bromoethyl group Chemical group 0.000 description 4
- HOZLOOPIXHWKCI-UHFFFAOYSA-N 2-chloro-n-methylacetamide Chemical compound CNC(=O)CCl HOZLOOPIXHWKCI-UHFFFAOYSA-N 0.000 description 4
- LQBHAQNUNMIJIW-UHFFFAOYSA-N 3-[1-(2-aminoethyl)piperidin-4-yl]-n,n-dipropylpropan-1-amine Chemical compound CCCN(CCC)CCCC1CCN(CCN)CC1 LQBHAQNUNMIJIW-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- BFQYYNBPHZJTCO-UHFFFAOYSA-N 9-methyl-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carbonyl chloride Chemical compound ClC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=C(C)C=C21 BFQYYNBPHZJTCO-UHFFFAOYSA-N 0.000 description 4
- 229930003347 Atropine Natural products 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 238000007605 air drying Methods 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 4
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 4
- 229960000396 atropine Drugs 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229910052987 metal hydride Inorganic materials 0.000 description 4
- 150000004681 metal hydrides Chemical class 0.000 description 4
- WTIYGHQFUHZRDA-UHFFFAOYSA-N n-ethyl-n-(piperidin-2-ylmethyl)ethanamine Chemical compound CCN(CC)CC1CCCCN1 WTIYGHQFUHZRDA-UHFFFAOYSA-N 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000002268 wool Anatomy 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- BEWIVDPTKCLTFS-UHFFFAOYSA-N 2-[2-[(dipropylamino)methyl]piperidin-1-yl]acetonitrile Chemical compound CCCN(CCC)CC1CCCCN1CC#N BEWIVDPTKCLTFS-UHFFFAOYSA-N 0.000 description 3
- UDOCKQLRTIVIQY-UHFFFAOYSA-N 2-[4-(3-piperidin-1-ylpropyl)piperidin-1-yl]ethanamine Chemical compound C1CN(CCN)CCC1CCCN1CCCCC1 UDOCKQLRTIVIQY-UHFFFAOYSA-N 0.000 description 3
- YXJIIUNAARHQOA-UHFFFAOYSA-N 2-[4-(4-piperidin-1-ylbutyl)piperidin-1-yl]ethanamine Chemical compound C1CN(CCN)CCC1CCCCN1CCCCC1 YXJIIUNAARHQOA-UHFFFAOYSA-N 0.000 description 3
- XUVXNZNNPAJYOR-UHFFFAOYSA-N 3-[1-(2-aminoethyl)piperidin-4-yl]-n,n-di(propan-2-yl)propan-1-amine Chemical compound CC(C)N(C(C)C)CCCC1CCN(CCN)CC1 XUVXNZNNPAJYOR-UHFFFAOYSA-N 0.000 description 3
- VOTNWGLOTJONDZ-UHFFFAOYSA-N 3-[1-(2-aminoethyl)piperidin-4-yl]-n,n-diethylpropan-1-amine Chemical compound CCN(CC)CCCC1CCN(CCN)CC1 VOTNWGLOTJONDZ-UHFFFAOYSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 3
- 150000004292 cyclic ethers Chemical class 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 3
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- PCDGHYIREOOHMR-UHFFFAOYSA-N n,n-diethyl-4-piperidin-4-ylbutan-1-amine Chemical compound CCN(CC)CCCCC1CCNCC1 PCDGHYIREOOHMR-UHFFFAOYSA-N 0.000 description 3
- NATBKMYWQICICI-UHFFFAOYSA-N n-[2-[2-(diethylaminomethyl)piperidin-1-yl]ethyl]-1-methyl-4-oxo-5h-thieno[3,4-b][1,5]benzodiazepine-10-carboxamide Chemical compound CCN(CC)CC1CCCCN1CCNC(=O)N1C2=CC=CC=C2NC(=O)C2=CSC(C)=C21 NATBKMYWQICICI-UHFFFAOYSA-N 0.000 description 3
- DBMBSNBKOZMJLV-UHFFFAOYSA-N n-[[1-(2-aminoethyl)piperidin-2-yl]methyl]-n-propylpropan-1-amine Chemical compound CCCN(CCC)CC1CCCCN1CCN DBMBSNBKOZMJLV-UHFFFAOYSA-N 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 2
- AAUUCDYRPRKIOH-UHFFFAOYSA-N 1,4-benzodiazepin-6-one;hydrochloride Chemical compound Cl.N1=CC=NC=C2C(=O)C=CC=C21 AAUUCDYRPRKIOH-UHFFFAOYSA-N 0.000 description 2
- DUPMSKQZFXUIJJ-UHFFFAOYSA-N 1-(4-piperidin-4-ylbutyl)piperidine Chemical compound C1CNCCC1CCCCN1CCCCC1 DUPMSKQZFXUIJJ-UHFFFAOYSA-N 0.000 description 2
- MEWSDQRQYWRYKZ-UHFFFAOYSA-N 1-[2-(diethylaminomethyl)piperidin-1-yl]-2-methylpropan-2-amine Chemical compound CCN(CC)CC1CCCCN1CC(C)(C)N MEWSDQRQYWRYKZ-UHFFFAOYSA-N 0.000 description 2
- PCIYJZJSZGJXRH-UHFFFAOYSA-N 1-methyl-5,10-dihydrothieno[3,4-b][1,5]benzodiazepin-4-one Chemical compound N1C2=CC=CC=C2NC(=O)C2=CSC(C)=C21 PCIYJZJSZGJXRH-UHFFFAOYSA-N 0.000 description 2
- XEIHFICROGCUBM-UHFFFAOYSA-N 2-[1-(2-aminoethyl)piperidin-2-yl]-n,n-dimethylethanamine Chemical compound CN(C)CCC1CCCCN1CCN XEIHFICROGCUBM-UHFFFAOYSA-N 0.000 description 2
- OQBNPTGVFHPEAM-UHFFFAOYSA-N 2-[1-(2-aminoethyl)piperidin-4-yl]-n,n-diethylethanamine Chemical compound CCN(CC)CCC1CCN(CCN)CC1 OQBNPTGVFHPEAM-UHFFFAOYSA-N 0.000 description 2
- JKPNVIXUOXOPLP-UHFFFAOYSA-N 2-[2-(4-piperidin-1-ylbutyl)piperidin-1-yl]acetonitrile Chemical compound N#CCN1CCCCC1CCCCN1CCCCC1 JKPNVIXUOXOPLP-UHFFFAOYSA-N 0.000 description 2
- OGGGOVYKFLKDRV-UHFFFAOYSA-N 2-[2-(diethylaminomethyl)piperidin-1-yl]-n-methylacetamide Chemical compound CCN(CC)CC1CCCCN1CC(=O)NC OGGGOVYKFLKDRV-UHFFFAOYSA-N 0.000 description 2
- MVTBUIBKCBFHHR-UHFFFAOYSA-N 2-[2-(diethylaminomethyl)piperidin-1-yl]-n-methylethanamine Chemical compound CCN(CC)CC1CCCCN1CCNC MVTBUIBKCBFHHR-UHFFFAOYSA-N 0.000 description 2
- SIZDTHUYXNZTEU-UHFFFAOYSA-N 2-[2-(diethylaminomethyl)pyrrolidin-1-yl]acetonitrile Chemical compound CCN(CC)CC1CCCN1CC#N SIZDTHUYXNZTEU-UHFFFAOYSA-N 0.000 description 2
- XNJRLXMJRMXNPJ-UHFFFAOYSA-N 2-[2-(diethylaminomethyl)pyrrolidin-1-yl]ethanamine Chemical compound CCN(CC)CC1CCCN1CCN XNJRLXMJRMXNPJ-UHFFFAOYSA-N 0.000 description 2
- LSQOVDMITMQRIY-UHFFFAOYSA-N 2-[2-(morpholin-4-ylmethyl)piperidin-1-yl]ethanamine Chemical compound NCCN1CCCCC1CN1CCOCC1 LSQOVDMITMQRIY-UHFFFAOYSA-N 0.000 description 2
- OTVYEHQGMSVXIP-UHFFFAOYSA-N 2-[2-[(cyclopentylmethylamino)methyl]piperidin-1-yl]acetonitrile Chemical compound N#CCN1CCCCC1CNCC1CCCC1 OTVYEHQGMSVXIP-UHFFFAOYSA-N 0.000 description 2
- HTDJNJVGHWEJLZ-UHFFFAOYSA-N 2-[2-[2-(diethylamino)ethyl]piperidin-1-yl]-n-methylacetamide Chemical compound CCN(CC)CCC1CCCCN1CC(=O)NC HTDJNJVGHWEJLZ-UHFFFAOYSA-N 0.000 description 2
- WZJYXZMOFHFNIP-UHFFFAOYSA-N 2-[2-[2-(diethylamino)ethyl]pyrrolidin-1-yl]acetonitrile Chemical compound CCN(CC)CCC1CCCN1CC#N WZJYXZMOFHFNIP-UHFFFAOYSA-N 0.000 description 2
- LUARUHNYCYYJFB-UHFFFAOYSA-N 2-[2-[[di(propan-2-yl)amino]methyl]piperidin-1-yl]acetonitrile Chemical compound CC(C)N(C(C)C)CC1CCCCN1CC#N LUARUHNYCYYJFB-UHFFFAOYSA-N 0.000 description 2
- DVXXIMDHWIQBIT-UHFFFAOYSA-N 2-[2-[[ethyl(propyl)amino]methyl]piperidin-1-yl]acetonitrile Chemical compound CCCN(CC)CC1CCCCN1CC#N DVXXIMDHWIQBIT-UHFFFAOYSA-N 0.000 description 2
- DMEXNPICXGHCAD-UHFFFAOYSA-N 2-[3-(3-piperidin-1-ylpropyl)piperidin-1-yl]ethanamine Chemical compound C1N(CCN)CCCC1CCCN1CCCCC1 DMEXNPICXGHCAD-UHFFFAOYSA-N 0.000 description 2
- QRRRISRPASYBGN-UHFFFAOYSA-N 2-[3-(4-pyrrolidin-1-ylbutyl)piperidin-1-yl]acetonitrile Chemical compound C1N(CC#N)CCCC1CCCCN1CCCC1 QRRRISRPASYBGN-UHFFFAOYSA-N 0.000 description 2
- ZDQRMIXOMTUPAN-UHFFFAOYSA-N 2-[3-(azepan-1-ylmethyl)piperidin-1-yl]acetonitrile Chemical compound C1N(CC#N)CCCC1CN1CCCCCC1 ZDQRMIXOMTUPAN-UHFFFAOYSA-N 0.000 description 2
- GXLIOBUGYXGUHM-UHFFFAOYSA-N 2-[3-(diethylamino)azepan-1-yl]acetonitrile Chemical compound CCN(CC)C1CCCCN(CC#N)C1 GXLIOBUGYXGUHM-UHFFFAOYSA-N 0.000 description 2
- CGZRVELCJJPHLK-UHFFFAOYSA-N 2-[3-(diethylaminomethyl)morpholin-4-yl]acetonitrile Chemical compound CCN(CC)CC1COCCN1CC#N CGZRVELCJJPHLK-UHFFFAOYSA-N 0.000 description 2
- ZMKGXNKEYOLREP-UHFFFAOYSA-N 2-[3-(diethylaminomethyl)piperidin-1-yl]acetonitrile Chemical compound CCN(CC)CC1CCCN(CC#N)C1 ZMKGXNKEYOLREP-UHFFFAOYSA-N 0.000 description 2
- FSCOLCCHBKFSOB-UHFFFAOYSA-N 2-[3-[(cyclohexylmethylamino)methyl]pyrrolidin-1-yl]acetonitrile Chemical compound C1N(CC#N)CCC1CNCC1CCCCC1 FSCOLCCHBKFSOB-UHFFFAOYSA-N 0.000 description 2
- CWVBELGUFBJTSY-UHFFFAOYSA-N 2-[3-[(dipropylamino)methyl]piperidin-1-yl]acetonitrile Chemical compound CCCN(CCC)CC1CCCN(CC#N)C1 CWVBELGUFBJTSY-UHFFFAOYSA-N 0.000 description 2
- ZUCFCQNXWSOAIE-UHFFFAOYSA-N 2-[3-[(dipropylamino)methyl]pyrrolidin-1-yl]acetonitrile Chemical compound CCCN(CCC)CC1CCN(CC#N)C1 ZUCFCQNXWSOAIE-UHFFFAOYSA-N 0.000 description 2
- FCIYGKPWYIEMAT-UHFFFAOYSA-N 2-[3-[4-(dimethylamino)butyl]piperidin-1-yl]acetonitrile Chemical compound CN(C)CCCCC1CCCN(CC#N)C1 FCIYGKPWYIEMAT-UHFFFAOYSA-N 0.000 description 2
- ZWMWXEWQEHHLEQ-UHFFFAOYSA-N 2-[4-(diethylaminomethyl)piperidin-1-yl]ethanamine Chemical compound CCN(CC)CC1CCN(CCN)CC1 ZWMWXEWQEHHLEQ-UHFFFAOYSA-N 0.000 description 2
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 2
- MEQBJJUWDCYIAB-UHFFFAOYSA-N 2-chloropyridin-3-amine Chemical compound NC1=CC=CN=C1Cl MEQBJJUWDCYIAB-UHFFFAOYSA-N 0.000 description 2
- CXFZFEJJLNLOTA-UHFFFAOYSA-N 4-[(3-chlorophenyl)carbamoyloxy]but-2-ynyl-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC#CCOC(=O)NC1=CC=CC(Cl)=C1 CXFZFEJJLNLOTA-UHFFFAOYSA-N 0.000 description 2
- RRACBBXZEKLQBB-UHFFFAOYSA-N 4-[1-(2-aminoethyl)piperidin-3-yl]-n,n-diethylbutan-1-amine Chemical compound CCN(CC)CCCCC1CCCN(CCN)C1 RRACBBXZEKLQBB-UHFFFAOYSA-N 0.000 description 2
- OEFOCCNYNSBSSQ-UHFFFAOYSA-N 4-[1-(2-aminoethyl)piperidin-3-yl]-n,n-dimethylbutan-1-amine Chemical compound CN(C)CCCCC1CCCN(CCN)C1 OEFOCCNYNSBSSQ-UHFFFAOYSA-N 0.000 description 2
- VWGAJURXTMJRSV-UHFFFAOYSA-N 4-[2-[(dimethylamino)methyl]piperidin-1-yl]-n-methylbutan-1-amine Chemical compound CNCCCCN1CCCCC1CN(C)C VWGAJURXTMJRSV-UHFFFAOYSA-N 0.000 description 2
- CQPGDDAKTTWVDD-UHFFFAOYSA-N 4-bromobutanenitrile Chemical compound BrCCCC#N CQPGDDAKTTWVDD-UHFFFAOYSA-N 0.000 description 2
- MIRBIZDDMSFTKY-UHFFFAOYSA-N 5,11-dihydropyrido[2,3-b][1,4]benzodiazepin-6-one Chemical compound O=C1NC2=CC=CN=C2NC2=CC=CC=C12 MIRBIZDDMSFTKY-UHFFFAOYSA-N 0.000 description 2
- NYIPTFLPZIVDFG-UHFFFAOYSA-N 5-oxo-6h-pyrido[3,2-c][1,5]benzodiazepine-11-carbonyl chloride Chemical compound N1C(=O)C2=CC=CN=C2N(C(=O)Cl)C2=CC=CC=C21 NYIPTFLPZIVDFG-UHFFFAOYSA-N 0.000 description 2
- XMGFXGDLTYQJJY-UHFFFAOYSA-N 6-[2-(diethylaminomethyl)piperidin-1-yl]hexan-1-amine Chemical compound CCN(CC)CC1CCCCN1CCCCCCN XMGFXGDLTYQJJY-UHFFFAOYSA-N 0.000 description 2
- KBGKIBMLEOGEBH-UHFFFAOYSA-N 6-oxo-n-[2-[2-(piperidin-1-ylmethyl)piperidin-1-yl]ethyl]-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide;hydrochloride Chemical compound Cl.C12=CC=CC=C2C(=O)NC2=CC=CN=C2N1C(=O)NCCN1CCCCC1CN1CCCCC1 KBGKIBMLEOGEBH-UHFFFAOYSA-N 0.000 description 2
- UDJBLLBMXWXSSW-UHFFFAOYSA-N 6-oxo-n-[2-[3-(4-pyrrolidin-1-ylbutyl)piperidin-1-yl]ethyl]-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide;dihydrochloride Chemical group Cl.Cl.C12=CC=CC=C2C(=O)NC2=CC=CN=C2N1C(=O)NCCN(C1)CCCC1CCCCN1CCCC1 UDJBLLBMXWXSSW-UHFFFAOYSA-N 0.000 description 2
- YGHADKSPGSWHQS-UHFFFAOYSA-N 8-ethyl-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carbonyl chloride Chemical compound N1C(=O)C2=CC(CC)=CC=C2N(C(Cl)=O)C2=NC=CC=C21 YGHADKSPGSWHQS-UHFFFAOYSA-N 0.000 description 2
- GJKMWZLKQRUYQS-UHFFFAOYSA-N 9-methyl-5,11-dihydropyrido[2,3-b][1,4]benzodiazepin-6-one Chemical compound N1C2=NC=CC=C2NC(=O)C2=CC=C(C)C=C12 GJKMWZLKQRUYQS-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- MMGYNSSWEUQWAS-UHFFFAOYSA-N Cl.Cl.N1=CC=NC=C2C(=O)C=CC=C21 Chemical compound Cl.Cl.N1=CC=NC=C2C(=O)C=CC=C21 MMGYNSSWEUQWAS-UHFFFAOYSA-N 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- MZDYABXXPZNUCT-UHFFFAOYSA-N N-[2-[2-[(dipropylamino)methyl]-1-piperidinyl]ethyl]-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound CCCN(CCC)CC1CCCCN1CCNC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 MZDYABXXPZNUCT-UHFFFAOYSA-N 0.000 description 2
- IYCRIRXXMRTZQX-XDDQGNLKSA-N O[C@@H]1CC[C@H](CC1)CNCC1N(CCCC1)CCN Chemical compound O[C@@H]1CC[C@H](CC1)CNCC1N(CCCC1)CCN IYCRIRXXMRTZQX-XDDQGNLKSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 101150046432 Tril gene Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 239000010617 anise oil Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 229950005499 carbon tetrachloride Drugs 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 2
- 210000003499 exocrine gland Anatomy 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- ANAFTYVSHCSQPP-UHFFFAOYSA-N lithium;trimethoxyalumane Chemical compound [Li].CO[Al](OC)OC ANAFTYVSHCSQPP-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960001383 methylscopolamine Drugs 0.000 description 2
- 239000003149 muscarinic antagonist Substances 0.000 description 2
- OAJBLGVEZPYPSE-UHFFFAOYSA-N n,n-diethyl-2-piperidin-2-ylethanamine Chemical compound CCN(CC)CCC1CCCCN1 OAJBLGVEZPYPSE-UHFFFAOYSA-N 0.000 description 2
- TVQYLBWVRBQOGI-UHFFFAOYSA-N n,n-dimethyl-1-piperidin-2-ylmethanamine Chemical compound CN(C)CC1CCCCN1 TVQYLBWVRBQOGI-UHFFFAOYSA-N 0.000 description 2
- BWOZIMUITPZKID-UHFFFAOYSA-N n-(2-bromoethyl)-1-methyl-4-oxo-5h-thieno[3,4-b][1,5]benzodiazepine-10-carboxamide Chemical compound BrCCNC(=O)N1C2=CC=CC=C2NC(=O)C2=CSC(C)=C21 BWOZIMUITPZKID-UHFFFAOYSA-N 0.000 description 2
- WLPTWYFHIDBVGB-UHFFFAOYSA-N n-(2-bromoethyl)-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound O=C1NC2=CC=CN=C2N(C(=O)NCCBr)C2=CC=CC=C21 WLPTWYFHIDBVGB-UHFFFAOYSA-N 0.000 description 2
- XHKTWEJGYQJWKS-UHFFFAOYSA-N n-[2-[2-(azepan-1-ylmethyl)piperidin-1-yl]ethyl]-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound C12=CC=CC=C2C(=O)NC2=CC=CN=C2N1C(=O)NCCN1CCCCC1CN1CCCCCC1 XHKTWEJGYQJWKS-UHFFFAOYSA-N 0.000 description 2
- YVVRLZQGWHJKGB-UHFFFAOYSA-N n-[2-[2-(diethylaminomethyl)piperidin-1-yl]ethyl]-5-oxo-6h-pyrido[3,2-c][1,5]benzodiazepine-11-carboxamide Chemical group CCN(CC)CC1CCCCN1CCNC(=O)N1C2=NC=CC=C2C(=O)NC2=CC=CC=C21 YVVRLZQGWHJKGB-UHFFFAOYSA-N 0.000 description 2
- WOCPAXGCWSOILA-UHFFFAOYSA-N n-[2-[2-(diethylaminomethyl)piperidin-1-yl]ethyl]-8-ethyl-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound CCN(CC)CC1CCCCN1CCNC(=O)N1C2=NC=CC=C2NC(=O)C2=CC(CC)=CC=C21 WOCPAXGCWSOILA-UHFFFAOYSA-N 0.000 description 2
- LBXOPAJGAXATCZ-UHFFFAOYSA-N n-[2-[2-[(dipropylamino)methyl]piperidin-1-yl]ethyl]-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.CCCN(CCC)CC1CCCCN1CCNC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 LBXOPAJGAXATCZ-UHFFFAOYSA-N 0.000 description 2
- UPDLODWOIMVKMH-UHFFFAOYSA-N n-[2-[4-[3-[di(propan-2-yl)amino]propyl]piperidin-1-yl]ethyl]-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound C1CC(CCCN(C(C)C)C(C)C)CCN1CCNC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 UPDLODWOIMVKMH-UHFFFAOYSA-N 0.000 description 2
- XBWOHPVAWLMCKV-UHFFFAOYSA-N n-[[1-(2-aminoethyl)piperidin-2-yl]methyl]-n-ethylpropan-1-amine Chemical compound CCCN(CC)CC1CCCCN1CCN XBWOHPVAWLMCKV-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 235000021395 porridge Nutrition 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 229960001462 sodium cyclamate Drugs 0.000 description 2
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000000213 tachycardiac effect Effects 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ZMZWUZSDXBEXGE-UHFFFAOYSA-N thieno[3,4-b][1,5]benzodiazepin-4-one Chemical compound O=C1N=C2C=CC=CC2=NC2=CSC=C12 ZMZWUZSDXBEXGE-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 description 1
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- SAYKZWPCENNSDR-UHFFFAOYSA-M (n-methylanilino)-triphenylphosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)N(C)C1=CC=CC=C1 SAYKZWPCENNSDR-UHFFFAOYSA-M 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 description 1
- XLWQILMRFOMPNX-UHFFFAOYSA-N 1,3-dimethyl-4-oxo-5h-pyrazolo[3,4-c][1,5]benzodiazepine-10-carbonyl chloride Chemical compound ClC(=O)N1C2=CC=CC=C2NC(=O)C2=C1C(C)=NN2C XLWQILMRFOMPNX-UHFFFAOYSA-N 0.000 description 1
- GUJAGMICFDYKNR-UHFFFAOYSA-N 1,4-benzodiazepine Chemical compound N1C=CN=CC2=CC=CC=C12 GUJAGMICFDYKNR-UHFFFAOYSA-N 0.000 description 1
- KWULWMUTIBFSHV-UHFFFAOYSA-N 1-(2-methyl-2-nitropropyl)piperidine Chemical compound [O-][N+](=O)C(C)(C)CN1CCCCC1 KWULWMUTIBFSHV-UHFFFAOYSA-N 0.000 description 1
- FKYVHDSPGMMDFF-UHFFFAOYSA-N 1-(2-piperidin-4-ylethyl)piperidine Chemical compound C1CNCCC1CCN1CCCCC1 FKYVHDSPGMMDFF-UHFFFAOYSA-N 0.000 description 1
- KMFDUBLMWFXIOU-UHFFFAOYSA-N 1-(3-piperidin-4-ylpropyl)piperidine Chemical compound C1CCCCN1CCCC1CCNCC1 KMFDUBLMWFXIOU-UHFFFAOYSA-N 0.000 description 1
- MBFFQCKXTJKYFD-UHFFFAOYSA-N 1-chloro-3-methyl-4-oxo-5h-pyrrolo[2,3-c][1,5]benzodiazepine-10-carbonyl chloride Chemical compound ClC(=O)N1C2=CC=CC=C2NC(=O)C2=C1C(Cl)=CN2C MBFFQCKXTJKYFD-UHFFFAOYSA-N 0.000 description 1
- BEGOSMMARJRWSD-UHFFFAOYSA-N 1-chloro-4-oxo-5h-thieno[3,4-b][1,5]benzodiazepine-10-carbonyl chloride Chemical compound O=C1NC2=CC=CC=C2N(C(=O)Cl)C2=C(Cl)SC=C21 BEGOSMMARJRWSD-UHFFFAOYSA-N 0.000 description 1
- OEIPMSFACRUEIH-UHFFFAOYSA-N 1-ethyl-3-(4-pyrrolidin-1-ylbutyl)piperidine Chemical compound N1(CCCC1)CCCCC1CN(CCC1)CC OEIPMSFACRUEIH-UHFFFAOYSA-N 0.000 description 1
- BITDXQFOLPBZAW-UHFFFAOYSA-N 1-methyl-4-oxo-5h-thieno[3,4-b][1,5]benzodiazepine-10-carbonyl chloride Chemical compound ClC(=O)N1C2=CC=CC=C2NC(=O)C2=CSC(C)=C21 BITDXQFOLPBZAW-UHFFFAOYSA-N 0.000 description 1
- FZXNMUKZEBCTLU-UHFFFAOYSA-N 1-methyl-4-oxo-n-[2-[4-(3-piperidin-1-ylpropyl)piperidin-1-yl]ethyl]-5h-thieno[3,4-b][1,5]benzodiazepine-10-carboxamide Chemical compound CC=1SC=C(C(NC2=CC=CC=C22)=O)C=1N2C(=O)NCCN(CC1)CCC1CCCN1CCCCC1 FZXNMUKZEBCTLU-UHFFFAOYSA-N 0.000 description 1
- LATPYPOOVXUNQQ-UHFFFAOYSA-N 1-piperidin-1-ylethanamine Chemical compound CC(N)N1CCCCC1 LATPYPOOVXUNQQ-UHFFFAOYSA-N 0.000 description 1
- UBRKDAVQCKZSPO-UHFFFAOYSA-N 11-[2-[2-(diethylaminomethyl)-1-piperidinyl]-1-oxoethyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one Chemical group CCN(CC)CC1CCCCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 UBRKDAVQCKZSPO-UHFFFAOYSA-N 0.000 description 1
- ZVAPWJGRRUHKGP-UHFFFAOYSA-N 1h-1,5-benzodiazepine Chemical compound N1C=CC=NC2=CC=CC=C12 ZVAPWJGRRUHKGP-UHFFFAOYSA-N 0.000 description 1
- UIKHKLFBHLPAPO-UHFFFAOYSA-N 2,3-diacetyl-2,3-dihydroxybutanedioic acid Chemical compound CC(=O)C(O)(C(O)=O)C(O)(C(C)=O)C(O)=O UIKHKLFBHLPAPO-UHFFFAOYSA-N 0.000 description 1
- GBJFSZCDZHSAOP-UHFFFAOYSA-N 2,3-dihydroxy-4-methoxy-4-oxobutanoic acid Chemical compound COC(=O)C(O)C(O)C(O)=O GBJFSZCDZHSAOP-UHFFFAOYSA-N 0.000 description 1
- NDTDVKKGYBULHF-UHFFFAOYSA-N 2-(1-hydroxy-3-phenylnaphthalen-2-yl)-3-phenylnaphthalen-1-ol Chemical compound C=1C2=CC=CC=C2C(O)=C(C=2C(=CC3=CC=CC=C3C=2O)C=2C=CC=CC=2)C=1C1=CC=CC=C1 NDTDVKKGYBULHF-UHFFFAOYSA-N 0.000 description 1
- ZXUNCOUPCYUAOF-UHFFFAOYSA-N 2-[1-(2-aminoethyl)piperidin-2-yl]-n,n-diethylethanamine Chemical compound CCN(CC)CCC1CCCCN1CCN ZXUNCOUPCYUAOF-UHFFFAOYSA-N 0.000 description 1
- LTDIUOFRHWKDTM-UHFFFAOYSA-N 2-[1-(2-aminoethyl)pyrrolidin-2-yl]-n,n-diethylethanamine Chemical compound CCN(CC)CCC1CCCN1CCN LTDIUOFRHWKDTM-UHFFFAOYSA-N 0.000 description 1
- KPISEEVVTBVONQ-UHFFFAOYSA-N 2-[2-(piperidin-1-ylmethyl)piperidin-1-yl]ethanamine Chemical compound NCCN1CCCCC1CN1CCCCC1 KPISEEVVTBVONQ-UHFFFAOYSA-N 0.000 description 1
- FHQYZDALKNQSRI-UHFFFAOYSA-N 2-[2-(pyrrolidin-1-ylmethyl)piperidin-1-yl]acetonitrile Chemical compound N#CCN1CCCCC1CN1CCCC1 FHQYZDALKNQSRI-UHFFFAOYSA-N 0.000 description 1
- YLYHBTLBYXXWDI-UHFFFAOYSA-N 2-[2-[(dimethylamino)methyl]piperidin-1-yl]-n-methylacetamide Chemical compound CNC(=O)CN1CCCCC1CN(C)C YLYHBTLBYXXWDI-UHFFFAOYSA-N 0.000 description 1
- GMSYDBLRCQGLSH-UHFFFAOYSA-N 2-[2-[(dimethylamino)methyl]piperidin-1-yl]ethanamine Chemical compound CN(C)CC1CCCCN1CCN GMSYDBLRCQGLSH-UHFFFAOYSA-N 0.000 description 1
- DIBFIXVTIOOXPK-UHFFFAOYSA-N 2-[2-[3-(dimethylamino)propyl]piperidin-1-yl]acetonitrile Chemical compound CN(C)CCCC1CCCCN1CC#N DIBFIXVTIOOXPK-UHFFFAOYSA-N 0.000 description 1
- KXGBBCSYCNBLGK-UHFFFAOYSA-N 2-[2-[4-(diethylamino)butyl]piperidin-1-yl]acetonitrile Chemical compound CCN(CC)CCCCC1CCCCN1CC#N KXGBBCSYCNBLGK-UHFFFAOYSA-N 0.000 description 1
- OXKZYUNGCBLXKA-UHFFFAOYSA-N 2-[2-[[butyl(ethyl)amino]methyl]piperidin-1-yl]acetonitrile Chemical compound CCCCN(CC)CC1CCCCN1CC#N OXKZYUNGCBLXKA-UHFFFAOYSA-N 0.000 description 1
- WPUXEMDIDCDZLG-UHFFFAOYSA-N 2-[3-(2-piperidin-1-ylethyl)piperidin-1-yl]acetonitrile Chemical compound C1N(CC#N)CCCC1CCN1CCCCC1 WPUXEMDIDCDZLG-UHFFFAOYSA-N 0.000 description 1
- YUCNYFJODQITTK-UHFFFAOYSA-N 2-[3-(3-piperidin-1-ylpropyl)piperidin-1-yl]acetonitrile Chemical compound C1N(CC#N)CCCC1CCCN1CCCCC1 YUCNYFJODQITTK-UHFFFAOYSA-N 0.000 description 1
- QKTDNUJUSBLJGG-UHFFFAOYSA-N 2-[3-(diethylaminomethyl)morpholin-4-yl]ethanamine Chemical compound CCN(CC)CC1COCCN1CCN QKTDNUJUSBLJGG-UHFFFAOYSA-N 0.000 description 1
- CIJXAFLVVBVFNQ-UHFFFAOYSA-N 2-[3-(diethylaminomethyl)piperidin-1-yl]ethanamine Chemical compound CCN(CC)CC1CCCN(CCN)C1 CIJXAFLVVBVFNQ-UHFFFAOYSA-N 0.000 description 1
- VINXMRBEHSLGFQ-UHFFFAOYSA-N 2-[3-(diethylaminomethyl)pyrrolidin-1-yl]acetonitrile Chemical compound CCN(CC)CC1CCN(CC#N)C1 VINXMRBEHSLGFQ-UHFFFAOYSA-N 0.000 description 1
- ZOOMESRIAINYNZ-UHFFFAOYSA-N 2-[3-(piperidin-1-ylmethyl)piperidin-1-yl]acetonitrile Chemical compound C1N(CC#N)CCCC1CN1CCCCC1 ZOOMESRIAINYNZ-UHFFFAOYSA-N 0.000 description 1
- QWFDQBVRJFRFDY-UHFFFAOYSA-N 2-[3-(piperidin-1-ylmethyl)pyrrolidin-1-yl]ethanamine Chemical compound C1N(CCN)CCC1CN1CCCCC1 QWFDQBVRJFRFDY-UHFFFAOYSA-N 0.000 description 1
- AYBYSQHBQFEAOV-UHFFFAOYSA-N 2-[3-[(cyclohexylmethylamino)methyl]pyrrolidin-1-yl]ethanamine Chemical compound C1N(CCN)CCC1CNCC1CCCCC1 AYBYSQHBQFEAOV-UHFFFAOYSA-N 0.000 description 1
- CSJBYVJJVYJMNF-UHFFFAOYSA-N 2-amino-n-(2-chloropyridin-3-yl)-4-methylbenzamide Chemical compound NC1=CC(C)=CC=C1C(=O)NC1=CC=CN=C1Cl CSJBYVJJVYJMNF-UHFFFAOYSA-N 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 1
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- QXMNVLNEQNEXCP-UHFFFAOYSA-N 3-[1-(2-aminoethyl)piperidin-2-yl]-n,n-diethylpropan-1-amine Chemical compound CCN(CC)CCCC1CCCCN1CCN QXMNVLNEQNEXCP-UHFFFAOYSA-N 0.000 description 1
- ICAHUECTSPOWQY-UHFFFAOYSA-N 3-[1-(2-aminoethyl)piperidin-2-yl]-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCC1CCCCN1CCN ICAHUECTSPOWQY-UHFFFAOYSA-N 0.000 description 1
- BMZLCBYFLQXSRW-UHFFFAOYSA-N 3-[1-(2-aminoethyl)piperidin-4-yl]-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCC1CCN(CCN)CC1 BMZLCBYFLQXSRW-UHFFFAOYSA-N 0.000 description 1
- IKDVKXYFNXHWHO-UHFFFAOYSA-N 3-[2-(diethylaminomethyl)piperidin-1-yl]propan-1-amine Chemical compound CCN(CC)CC1CCCCN1CCCN IKDVKXYFNXHWHO-UHFFFAOYSA-N 0.000 description 1
- ITLQJUWUJYHNHU-UHFFFAOYSA-N 3-[2-(diethylaminomethyl)piperidin-1-yl]propanenitrile Chemical compound CCN(CC)CC1CCCCN1CCC#N ITLQJUWUJYHNHU-UHFFFAOYSA-N 0.000 description 1
- YYIVKUOVUZZZAZ-UHFFFAOYSA-N 3-[2-[(dimethylamino)methyl]piperidin-1-yl]propan-1-amine Chemical compound CN(C)CC1CCCCN1CCCN YYIVKUOVUZZZAZ-UHFFFAOYSA-N 0.000 description 1
- MLRJSEFBJMZYGV-UHFFFAOYSA-N 3-[2-[(dimethylamino)methyl]piperidin-1-yl]propanenitrile Chemical compound CN(C)CC1CCCCN1CCC#N MLRJSEFBJMZYGV-UHFFFAOYSA-N 0.000 description 1
- GDDNTTHUKVNJRA-UHFFFAOYSA-N 3-bromo-3,3-difluoroprop-1-ene Chemical compound FC(F)(Br)C=C GDDNTTHUKVNJRA-UHFFFAOYSA-N 0.000 description 1
- WUVIDLSATDZNQM-UHFFFAOYSA-N 3-piperidin-4-yl-n,n-di(propan-2-yl)propanamide Chemical compound CC(C)N(C(C)C)C(=O)CCC1CCNCC1 WUVIDLSATDZNQM-UHFFFAOYSA-N 0.000 description 1
- PHRVJDFGQUUHGJ-UHFFFAOYSA-N 3-piperidin-4-yl-n,n-dipropylpropan-1-amine Chemical compound CCCN(CCC)CCCC1CCNCC1 PHRVJDFGQUUHGJ-UHFFFAOYSA-N 0.000 description 1
- OSIHOPSTTAATCN-UHFFFAOYSA-N 4,6-dimethyl-8-oxo-2,5,6,9,14-pentazatricyclo[8.4.0.03,7]tetradeca-1(10),3(7),4,11,13-pentaene-2-carbonyl chloride Chemical compound ClC(=O)N1C2=NC=CC=C2NC(=O)C2=C1C(C)=NN2C OSIHOPSTTAATCN-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- JWBDHFRXISHFLK-UHFFFAOYSA-N 4-[1-(2-aminoethyl)piperidin-2-yl]-n,n-diethylbutan-1-amine Chemical compound CCN(CC)CCCCC1CCCCN1CCN JWBDHFRXISHFLK-UHFFFAOYSA-N 0.000 description 1
- UVOKOJCBZHTDCX-UHFFFAOYSA-N 4-[2-(diethylaminomethyl)piperidin-1-yl]-n-methylbutan-1-amine Chemical compound CCN(CC)CC1CCCCN1CCCCNC UVOKOJCBZHTDCX-UHFFFAOYSA-N 0.000 description 1
- VIJLZDHIRXBMKQ-UHFFFAOYSA-N 4-[2-(diethylaminomethyl)piperidin-1-yl]butan-1-amine Chemical compound CCN(CC)CC1CCCCN1CCCCN VIJLZDHIRXBMKQ-UHFFFAOYSA-N 0.000 description 1
- BYSDNLZIZBYUOX-UHFFFAOYSA-N 4-[2-[(dimethylamino)methyl]piperidin-1-yl]butan-1-amine Chemical compound CN(C)CC1CCCCN1CCCCN BYSDNLZIZBYUOX-UHFFFAOYSA-N 0.000 description 1
- UDNHXUYSYICQCP-UHFFFAOYSA-N 4-[3-(1-methylpyrrolidin-2-yl)propyl]piperidine Chemical compound CN1CCCC1CCCC1CCNCC1 UDNHXUYSYICQCP-UHFFFAOYSA-N 0.000 description 1
- WRFYIYOXJWKONR-UHFFFAOYSA-N 4-bromo-2-methoxyaniline Chemical compound COC1=CC(Br)=CC=C1N WRFYIYOXJWKONR-UHFFFAOYSA-N 0.000 description 1
- PHOSWLARCIBBJZ-UHFFFAOYSA-N 6-bromohexanenitrile Chemical compound BrCCCCCC#N PHOSWLARCIBBJZ-UHFFFAOYSA-N 0.000 description 1
- NABQSYQPATYLDS-UHFFFAOYSA-N 6-oxo-5,11-dihydropyrido[2,3-b][1,4]benzodiazepine-2-carbonyl chloride Chemical compound N1C(=O)C2=CC=CC=C2NC2=NC(C(=O)Cl)=CC=C21 NABQSYQPATYLDS-UHFFFAOYSA-N 0.000 description 1
- YWRZHOVOAKGOEQ-UHFFFAOYSA-N 6-oxo-5h-benzo[b][1,4]benzodiazepine-11-carbonyl chloride Chemical compound N1C(=O)C2=CC=CC=C2N(C(=O)Cl)C2=CC=CC=C21 YWRZHOVOAKGOEQ-UHFFFAOYSA-N 0.000 description 1
- WPQHVWDEGMMAII-UHFFFAOYSA-N 6-oxo-n-[2-[2-(pyrrolidin-1-ylmethyl)piperidin-1-yl]ethyl]-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound C12=CC=CC=C2C(=O)NC2=CC=CN=C2N1C(=O)NCCN1CCCCC1CN1CCCC1 WPQHVWDEGMMAII-UHFFFAOYSA-N 0.000 description 1
- HFQXVGUVVYVGIM-UHFFFAOYSA-N 6-oxo-n-[2-[3-(2-piperidin-1-ylethyl)piperidin-1-yl]ethyl]-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide;dihydrochloride Chemical group Cl.Cl.C12=CC=CC=C2C(=O)NC2=CC=CN=C2N1C(=O)NCCN(C1)CCCC1CCN1CCCCC1 HFQXVGUVVYVGIM-UHFFFAOYSA-N 0.000 description 1
- STVYTKHGGZXAOA-UHFFFAOYSA-N 6-oxo-n-[2-[3-(piperidin-1-ylmethyl)piperidin-1-yl]ethyl]-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide;dihydrochloride Chemical compound Cl.Cl.C12=CC=CC=C2C(=O)NC2=CC=CN=C2N1C(=O)NCCN(C1)CCCC1CN1CCCCC1 STVYTKHGGZXAOA-UHFFFAOYSA-N 0.000 description 1
- WIHPVGQBXNFUQE-UHFFFAOYSA-N 6-oxo-n-[2-[3-(piperidin-1-ylmethyl)pyrrolidin-1-yl]ethyl]-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound C12=CC=CC=C2C(=O)NC2=CC=CN=C2N1C(=O)NCCN(C1)CCC1CN1CCCCC1 WIHPVGQBXNFUQE-UHFFFAOYSA-N 0.000 description 1
- PTWWBUSCABXSKA-UHFFFAOYSA-N 6-oxo-n-[2-[4-(4-piperidin-1-ylbutyl)piperidin-1-yl]ethyl]-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide;dihydrochloride Chemical compound Cl.Cl.C12=CC=CC=C2C(=O)NC2=CC=CN=C2N1C(=O)NCCN(CC1)CCC1CCCCN1CCCCC1 PTWWBUSCABXSKA-UHFFFAOYSA-N 0.000 description 1
- GTLRIDZPFGZQLV-UHFFFAOYSA-N 7-fluoro-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carbonyl chloride Chemical compound ClC(=O)N1C2=NC=CC=C2NC(=O)C2=C1C=CC=C2F GTLRIDZPFGZQLV-UHFFFAOYSA-N 0.000 description 1
- SZMAXCNQRQFOTO-UHFFFAOYSA-N 8-bromo-5,11-dihydropyrido[2,3-b][1,4]benzodiazepin-6-one Chemical compound N1C(=O)C2=CC(Br)=CC=C2NC2=NC=CC=C21 SZMAXCNQRQFOTO-UHFFFAOYSA-N 0.000 description 1
- HJKNLUUBVWPBED-UHFFFAOYSA-N 8-bromo-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carbonyl chloride Chemical compound O=C1NC2=CC=CN=C2N(C(=O)Cl)C2=CC=C(Br)C=C21 HJKNLUUBVWPBED-UHFFFAOYSA-N 0.000 description 1
- MLSONZRFMOFYMC-UHFFFAOYSA-N 8-chloro-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carbonyl chloride Chemical compound O=C1NC2=CC=CN=C2N(C(=O)Cl)C2=CC=C(Cl)C=C21 MLSONZRFMOFYMC-UHFFFAOYSA-N 0.000 description 1
- NTHUABKRXFCWTR-UHFFFAOYSA-N 8-ethyl-5,11-dihydropyrido[2,3-b][1,4]benzodiazepin-6-one Chemical compound N1C(=O)C2=CC(CC)=CC=C2NC2=NC=CC=C21 NTHUABKRXFCWTR-UHFFFAOYSA-N 0.000 description 1
- QAVPJKJDAMHQEU-UHFFFAOYSA-N 8-methyl-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carbonyl chloride Chemical compound N1C(=O)C2=CC(C)=CC=C2N(C(Cl)=O)C2=NC=CC=C21 QAVPJKJDAMHQEU-UHFFFAOYSA-N 0.000 description 1
- WQFVRJZUNKWMGJ-UHFFFAOYSA-N 9-chloro-6-oxo-n-[2-[4-(3-piperidin-1-ylpropyl)piperidin-1-yl]ethyl]-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound C=1C(Cl)=CC=C(C(NC2=CC=CN=C22)=O)C=1N2C(=O)NCCN(CC1)CCC1CCCN1CCCCC1 WQFVRJZUNKWMGJ-UHFFFAOYSA-N 0.000 description 1
- IABGIFJESXNJAY-UHFFFAOYSA-N 9-chloro-n-[2-[3-(diethylaminomethyl)pyrrolidin-1-yl]ethyl]-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound C1C(CN(CC)CC)CCN1CCNC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=C(Cl)C=C21 IABGIFJESXNJAY-UHFFFAOYSA-N 0.000 description 1
- GNYZDJNSPVWCOR-UHFFFAOYSA-N 9-chloro-n-[2-[4-[3-(diethylamino)propyl]piperidin-1-yl]ethyl]-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound C1CC(CCCN(CC)CC)CCN1CCNC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=C(Cl)C=C21 GNYZDJNSPVWCOR-UHFFFAOYSA-N 0.000 description 1
- RQMQOORNABKEOR-UHFFFAOYSA-N 9-fluoro-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carbonyl chloride Chemical compound ClC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=C(F)C=C21 RQMQOORNABKEOR-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- VAMGRPAPAFVIIU-UHFFFAOYSA-N C(=O)=C1C=CC=2C(=NC3=C(C(N=2)=O)C=CC=C3)N1 Chemical compound C(=O)=C1C=CC=2C(=NC3=C(C(N=2)=O)C=CC=C3)N1 VAMGRPAPAFVIIU-UHFFFAOYSA-N 0.000 description 1
- DUGOWIPKCNPIRJ-UHFFFAOYSA-N C1CC2=C(C=C1)N(C3=C(C=CC=C3Cl)NC2=O)C(=O)Cl Chemical compound C1CC2=C(C=C1)N(C3=C(C=CC=C3Cl)NC2=O)C(=O)Cl DUGOWIPKCNPIRJ-UHFFFAOYSA-N 0.000 description 1
- CTTHZUSHONFYIM-UHFFFAOYSA-N C1CCN(CC1)CCCCC2CCN(CC2)CCNC(=O)N3C4=C(C=CC(=C4)Cl)C(=O)NC5=C3N=CC=C5.Cl Chemical group C1CCN(CC1)CCCCC2CCN(CC2)CCNC(=O)N3C4=C(C=CC(=C4)Cl)C(=O)NC5=C3N=CC=C5.Cl CTTHZUSHONFYIM-UHFFFAOYSA-N 0.000 description 1
- SOPWNIZDXSLPQR-XDDQGNLKSA-N CNC(=O)CN1CCCCC1CNC[C@@H]1CC[C@@H](O)CC1 Chemical compound CNC(=O)CN1CCCCC1CNC[C@@H]1CC[C@@H](O)CC1 SOPWNIZDXSLPQR-XDDQGNLKSA-N 0.000 description 1
- NPIWPAGHCCCDGX-CMTYHBQSSA-N CNCCN1CCCCC1CNC[C@@H]1CC[C@@H](O)CC1 Chemical compound CNCCN1CCCCC1CNC[C@@H]1CC[C@@H](O)CC1 NPIWPAGHCCCDGX-CMTYHBQSSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- ZSKCYRQOFSOVNM-UHFFFAOYSA-K Cl.Cl[Ir](Cl)Cl Chemical compound Cl.Cl[Ir](Cl)Cl ZSKCYRQOFSOVNM-UHFFFAOYSA-K 0.000 description 1
- ACNTZJZMNCSWPV-UHFFFAOYSA-N Cl.O=C1N=C2C=CC=NC2=NC2=CC=CC=C12 Chemical compound Cl.O=C1N=C2C=CC=NC2=NC2=CC=CC=C12 ACNTZJZMNCSWPV-UHFFFAOYSA-N 0.000 description 1
- JEFGZXVZFZRGAZ-UHFFFAOYSA-N ClC(=O)N1C2=NC=CC=C2NC(=O)C2=C1C=NN2C Chemical compound ClC(=O)N1C2=NC=CC=C2NC(=O)C2=C1C=NN2C JEFGZXVZFZRGAZ-UHFFFAOYSA-N 0.000 description 1
- QDJYUDHCCXGWES-UHFFFAOYSA-N ClC1=CC2=C(C(NC3=C(N2C(=O)NCCN2C(CCCC2)CN(CC)CC)NCC=C3)=O)C=C1 Chemical compound ClC1=CC2=C(C(NC3=C(N2C(=O)NCCN2C(CCCC2)CN(CC)CC)NCC=C3)=O)C=C1 QDJYUDHCCXGWES-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- SKCKOFZKJLZSFA-UHFFFAOYSA-N L-Gulomethylit Natural products CC(O)C(O)C(O)C(O)CO SKCKOFZKJLZSFA-UHFFFAOYSA-N 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- MNHQHUAYQQRWKU-DHKXFDHISA-N O[C@@H]1CC[C@H](CC1)CNCC1NCCCC1 Chemical compound O[C@@H]1CC[C@H](CC1)CNCC1NCCCC1 MNHQHUAYQQRWKU-DHKXFDHISA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical group [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- XHKQACKHQFWLMO-UHFFFAOYSA-N S(=O)(=O)(O)O.N1=CC=NC=C2C1=CC=CC2=O Chemical compound S(=O)(=O)(O)O.N1=CC=NC=C2C1=CC=CC2=O XHKQACKHQFWLMO-UHFFFAOYSA-N 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 240000004668 Valerianella locusta Species 0.000 description 1
- 235000003560 Valerianella locusta Nutrition 0.000 description 1
- HGMITUYOCPPQLE-IBGZPJMESA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-diphenylacetate Chemical compound O([C@@H]1C2CCN(CC2)C1)C(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 HGMITUYOCPPQLE-IBGZPJMESA-N 0.000 description 1
- JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical compound [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical group 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910001516 alkali metal iodide Inorganic materials 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- 125000005219 aminonitrile group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- AYJRCSIUFZENHW-DEQYMQKBSA-L barium(2+);oxomethanediolate Chemical compound [Ba+2].[O-][14C]([O-])=O AYJRCSIUFZENHW-DEQYMQKBSA-L 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003426 co-catalyst Substances 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- GFHNAMRJFCEERV-UHFFFAOYSA-L cobalt chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Co+2] GFHNAMRJFCEERV-UHFFFAOYSA-L 0.000 description 1
- YYQXTQJPDOJRFO-UHFFFAOYSA-L cobalt(2+);dibenzoate;tetrahydrate Chemical compound O.O.O.O.[Co+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 YYQXTQJPDOJRFO-UHFFFAOYSA-L 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- YPVJRTMGYMODPQ-UHFFFAOYSA-N ethyl N-[2-[2-[2-(dimethylamino)ethyl]piperidin-1-yl]ethyl]carbamate Chemical compound C(C)OC(NCCN1C(CCCC1)CCN(C)C)=O YPVJRTMGYMODPQ-UHFFFAOYSA-N 0.000 description 1
- PXAPCDDGYGVLOR-UHFFFAOYSA-N ethyl N-[4-[2-(diethylaminomethyl)piperidin-1-yl]butyl]carbamate Chemical compound C(C)OC(NCCCCN1C(CCCC1)CN(CC)CC)=O PXAPCDDGYGVLOR-UHFFFAOYSA-N 0.000 description 1
- AGRQUJORFZRKKR-UHFFFAOYSA-N ethyl N-[4-[2-[(dimethylamino)methyl]piperidin-1-yl]butyl]carbamate Chemical compound C(C)OC(NCCCCN1C(CCCC1)CN(C)C)=O AGRQUJORFZRKKR-UHFFFAOYSA-N 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
- 229960002329 methacholine Drugs 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- VAQBJVZNPBNHGC-UHFFFAOYSA-N methyl 2-amino-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C=C1N VAQBJVZNPBNHGC-UHFFFAOYSA-N 0.000 description 1
- QVNYNHCNNGKULA-UHFFFAOYSA-N methyl 2-amino-5-bromobenzoate Chemical compound COC(=O)C1=CC(Br)=CC=C1N QVNYNHCNNGKULA-UHFFFAOYSA-N 0.000 description 1
- ZJDZGWIALYBAIL-UHFFFAOYSA-N methyl 2-amino-5-ethylbenzoate Chemical compound CCC1=CC=C(N)C(C(=O)OC)=C1 ZJDZGWIALYBAIL-UHFFFAOYSA-N 0.000 description 1
- VLVZDLJKSPADME-UHFFFAOYSA-N methyl N-[4-[2-(diethylaminomethyl)piperidin-1-yl]butyl]carbamate Chemical compound COC(NCCCCN1C(CCCC1)CN(CC)CC)=O VLVZDLJKSPADME-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- WWBRCYGPMKYDJN-VFIVCBTMSA-N n,n'-bis[(e)-[4-(dimethylamino)phenyl]methylideneamino]decanediamide Chemical compound C1=CC(N(C)C)=CC=C1\C=N\NC(=O)CCCCCCCCC(=O)N\N=C\C1=CC=C(N(C)C)C=C1 WWBRCYGPMKYDJN-VFIVCBTMSA-N 0.000 description 1
- UDBKTMMVEWIPAF-UHFFFAOYSA-N n,n-diethyl-2-[1-[2-(methylamino)ethyl]piperidin-2-yl]ethanamine Chemical compound CCN(CC)CCC1CCCCN1CCNC UDBKTMMVEWIPAF-UHFFFAOYSA-N 0.000 description 1
- LKFIRLHXHMMYGO-UHFFFAOYSA-N n,n-diethyl-2-piperidin-4-ylethanamine Chemical compound CCN(CC)CCC1CCNCC1 LKFIRLHXHMMYGO-UHFFFAOYSA-N 0.000 description 1
- KTPQNPQODXDJBK-UHFFFAOYSA-N n,n-diethyl-3-piperidin-2-ylpropan-1-amine Chemical compound CCN(CC)CCCC1CCCCN1 KTPQNPQODXDJBK-UHFFFAOYSA-N 0.000 description 1
- OKPWTHZKBRALMY-UHFFFAOYSA-N n,n-diethylazepan-3-amine Chemical compound CCN(CC)C1CCCCNC1 OKPWTHZKBRALMY-UHFFFAOYSA-N 0.000 description 1
- LJNOFMVJNGNICZ-UHFFFAOYSA-N n,n-dimethyl-2-[1-[2-(methylamino)ethyl]piperidin-2-yl]ethanamine Chemical compound CNCCN1CCCCC1CCN(C)C LJNOFMVJNGNICZ-UHFFFAOYSA-N 0.000 description 1
- LOPVGJYGIUVMGL-UHFFFAOYSA-N n,n-dimethyl-3-piperidin-2-ylpropan-1-amine Chemical compound CN(C)CCCC1CCCCN1 LOPVGJYGIUVMGL-UHFFFAOYSA-N 0.000 description 1
- FCXRIXCOWMIOJO-UHFFFAOYSA-N n-(2-bromoethyl)-9-chloro-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound BrCCNC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=C(Cl)C=C21 FCXRIXCOWMIOJO-UHFFFAOYSA-N 0.000 description 1
- ZJNADBATOJEWDB-UHFFFAOYSA-N n-(3-bromopropyl)-5,6-dihydropyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound C1NC2=CC=CN=C2N(C(=O)NCCCBr)C2=CC=CC=C21 ZJNADBATOJEWDB-UHFFFAOYSA-N 0.000 description 1
- JECMDTMOQOVPIU-UHFFFAOYSA-N n-(piperidin-2-ylmethyl)-n-propylpropan-1-amine Chemical compound CCCN(CCC)CC1CCCCN1 JECMDTMOQOVPIU-UHFFFAOYSA-N 0.000 description 1
- INSHBXGMMXZVIZ-UHFFFAOYSA-N n-[1-[2-(diethylaminomethyl)piperidin-1-yl]-2-methylpropan-2-yl]-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound CCN(CC)CC1CCCCN1CC(C)(C)NC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 INSHBXGMMXZVIZ-UHFFFAOYSA-N 0.000 description 1
- RVQHCCSDWZCZHL-UHFFFAOYSA-N n-[2-[2-(diethylaminomethyl)piperidin-1-yl]ethyl]-8-methyl-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound CCN(CC)CC1CCCCN1CCNC(=O)N1C2=NC=CC=C2NC(=O)C2=CC(C)=CC=C21 RVQHCCSDWZCZHL-UHFFFAOYSA-N 0.000 description 1
- QXLJMVVKHWVDQZ-UHFFFAOYSA-N n-[2-[2-(diethylaminomethyl)piperidin-1-yl]ethyl]-n-methyl-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound CCN(CC)CC1CCCCN1CCN(C)C(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 QXLJMVVKHWVDQZ-UHFFFAOYSA-N 0.000 description 1
- SDPVMXUJRDIGDS-UHFFFAOYSA-N n-[2-[2-[(dipropylamino)methyl]piperidin-1-yl]ethyl]-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide;hydrochloride Chemical compound Cl.CCCN(CCC)CC1CCCCN1CCNC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 SDPVMXUJRDIGDS-UHFFFAOYSA-N 0.000 description 1
- SGFAPGFCKWIENI-UHFFFAOYSA-N n-[2-[2-[2-(diethylamino)ethyl]piperidin-1-yl]ethyl]-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound CCN(CC)CCC1CCCCN1CCNC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 SGFAPGFCKWIENI-UHFFFAOYSA-N 0.000 description 1
- HZNAMUDDZMRARG-UHFFFAOYSA-N n-[2-[2-[2-(dimethylamino)ethyl]piperidin-1-yl]ethyl]-n-methyl-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound CN(C)CCC1CCCCN1CCN(C)C(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 HZNAMUDDZMRARG-UHFFFAOYSA-N 0.000 description 1
- DVJABXWETOFQGF-UHFFFAOYSA-N n-[2-[2-[3-(dimethylamino)propyl]piperidin-1-yl]ethyl]-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound CN(C)CCCC1CCCCN1CCNC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 DVJABXWETOFQGF-UHFFFAOYSA-N 0.000 description 1
- MGAAXDBJIVRHAI-UHFFFAOYSA-N n-[2-[2-[[butyl(ethyl)amino]methyl]piperidin-1-yl]ethyl]-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound CCCCN(CC)CC1CCCCN1CCNC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 MGAAXDBJIVRHAI-UHFFFAOYSA-N 0.000 description 1
- JUWKTQONHFELCH-UHFFFAOYSA-N n-[2-[2-[[ethyl(propyl)amino]methyl]piperidin-1-yl]ethyl]-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound CCCN(CC)CC1CCCCN1CCNC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 JUWKTQONHFELCH-UHFFFAOYSA-N 0.000 description 1
- UEPLSPZXEOBACM-UHFFFAOYSA-N n-[2-[3-(diethylaminomethyl)pyrrolidin-1-yl]ethyl]-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound C1C(CN(CC)CC)CCN1CCNC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 UEPLSPZXEOBACM-UHFFFAOYSA-N 0.000 description 1
- OVWSBDYDTMPTFR-UHFFFAOYSA-N n-[2-[4-[3-(diethylamino)propyl]piperidin-1-yl]ethyl]-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound C1CC(CCCN(CC)CC)CCN1CCNC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 OVWSBDYDTMPTFR-UHFFFAOYSA-N 0.000 description 1
- CJFWTKPJLNTZGT-UHFFFAOYSA-N n-[2-[4-[3-[di(propan-2-yl)amino]propyl]piperidin-1-yl]ethyl]-9-methyl-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound C1CC(CCCN(C(C)C)C(C)C)CCN1CCNC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=C(C)C=C21 CJFWTKPJLNTZGT-UHFFFAOYSA-N 0.000 description 1
- UOFCOWAQPBONSO-UHFFFAOYSA-N n-[2-[4-[4-(diethylamino)butyl]piperidin-1-yl]ethyl]-6-oxo-5h-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide Chemical compound C1CC(CCCCN(CC)CC)CCN1CCNC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 UOFCOWAQPBONSO-UHFFFAOYSA-N 0.000 description 1
- UZVNBJIKTCWIFD-UHFFFAOYSA-N n-[[1-(2-aminoethyl)piperidin-2-yl]methyl]-n-ethylbutan-1-amine Chemical compound CCCCN(CC)CC1CCCCN1CCN UZVNBJIKTCWIFD-UHFFFAOYSA-N 0.000 description 1
- BHYFHJJDCAJFMR-UHFFFAOYSA-N n-[[1-(2-aminoethyl)piperidin-3-yl]methyl]-n-propylpropan-1-amine Chemical compound CCCN(CCC)CC1CCCN(CCN)C1 BHYFHJJDCAJFMR-UHFFFAOYSA-N 0.000 description 1
- AQELNYDHMPFDGC-UHFFFAOYSA-N n-[[1-(2-aminoethyl)pyrrolidin-3-yl]methyl]-n-propylpropan-1-amine Chemical compound CCCN(CCC)CC1CCN(CCN)C1 AQELNYDHMPFDGC-UHFFFAOYSA-N 0.000 description 1
- NBCRICNNRIGTEM-UHFFFAOYSA-N n-ethyl-n-(piperidin-4-ylmethyl)ethanamine Chemical compound CCN(CC)CC1CCNCC1 NBCRICNNRIGTEM-UHFFFAOYSA-N 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- LAIZPRYFQUWUBN-UHFFFAOYSA-L nickel chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Ni+2] LAIZPRYFQUWUBN-UHFFFAOYSA-L 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- OQURWADGXKZUIH-UHFFFAOYSA-N osmium(4+) Chemical compound [Os+4] OQURWADGXKZUIH-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
- 229960004633 pirenzepine Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- CLSUSRZJUQMOHH-UHFFFAOYSA-L platinum dichloride Chemical compound Cl[Pt]Cl CLSUSRZJUQMOHH-UHFFFAOYSA-L 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- QYETZOYLEWPRIX-UHFFFAOYSA-N pyrido[2,3-b][1,4]benzodiazepin-6-one Chemical compound O=C1N=C2C=CC=NC2=NC2=CC=CC=C12 QYETZOYLEWPRIX-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004460 silage Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012419 sodium bis(2-methoxyethoxy)aluminum hydride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19863643666 DE3643666A1 (de) | 1986-12-20 | 1986-12-20 | Neue kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
DE3643666 | 1986-12-20 |
Publications (3)
Publication Number | Publication Date |
---|---|
DK669187D0 DK669187D0 (da) | 1987-12-18 |
DK669187A DK669187A (da) | 1988-06-21 |
DK170670B1 true DK170670B1 (da) | 1995-11-27 |
Family
ID=6316706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK669187A DK170670B1 (da) | 1986-12-20 | 1987-12-18 | Kondenserede diazepinoner, fremgangsmåde til deresfremstilling, lægemidler indeholdende en sådan diazepinon, samt anvendelse af sådanne diazepinoner til fremstilling af lægemidler |
Country Status (21)
Country | Link |
---|---|
US (1) | US4873236A (fi) |
EP (1) | EP0273239B1 (fi) |
JP (1) | JP2574348B2 (fi) |
KR (1) | KR950014867B1 (fi) |
AT (1) | ATE61367T1 (fi) |
AU (1) | AU596479B2 (fi) |
CA (1) | CA1320197C (fi) |
DD (1) | DD275243A5 (fi) |
DE (2) | DE3643666A1 (fi) |
DK (1) | DK170670B1 (fi) |
ES (1) | ES2021000B3 (fi) |
FI (1) | FI86725C (fi) |
GR (1) | GR3001933T3 (fi) |
HU (1) | HU199468B (fi) |
IE (1) | IE60265B1 (fi) |
IL (1) | IL84874A (fi) |
NO (1) | NO166645C (fi) |
NZ (1) | NZ222994A (fi) |
PH (1) | PH25579A (fi) |
PT (1) | PT86394B (fi) |
ZA (1) | ZA879492B (fi) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3820346A1 (de) * | 1988-06-15 | 1989-12-21 | Thomae Gmbh Dr K | Neue kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
DE3820347A1 (de) * | 1988-06-15 | 1989-12-21 | Thomae Gmbh Dr K | Verwendung von in 11-stellung substituierten 5,11-dihydro-6h-pyrido(2,3-b) (1,4)benzodiazepin-6-onen zur behandlung von bradycardien und bradyarrhythmien in der human- und veterinaermedizin |
US5366972A (en) * | 1989-04-20 | 1994-11-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection |
CA2030056C (en) * | 1989-11-17 | 1995-10-17 | Karl D. Hargrave | 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection |
US6057337A (en) * | 1998-02-02 | 2000-05-02 | Shiseido Co., Ltd. | 1,2-DI-substituted piperidine derivative, hair growth promoter and external composition for skin using the same |
WO2004011430A1 (ja) * | 2002-07-25 | 2004-02-05 | Yamanouchi Pharmaceutical Co., Ltd. | ナトリウムチャネル阻害剤 |
FR2850654A1 (fr) * | 2003-02-03 | 2004-08-06 | Servier Lab | Nouveaux derives d'azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1795183B1 (de) * | 1968-08-20 | 1972-07-20 | Thomae Gmbh Dr K | 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-on-derivate und Arzneimittel |
FI50242C (fi) * | 1969-07-18 | 1976-01-12 | Thomae Gmbh Dr K | Menetelmä valmistaa farmakologisesti aktiivisia uusia diallyyliaminoal kanoyylidibenso- tai pyridobenso-diatsepiineja ja niiden happoadditios uoloja. |
DE2424811C3 (de) * | 1974-05-22 | 1981-08-20 | Dr. Karl Thomae Gmbh, 7950 Biberach | Pyrido-benzodiazepinone, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
US4210648A (en) * | 1977-05-31 | 1980-07-01 | Boehringer Ingelheim Gmbh | II-Aminoacyl-5,11-dihydro-6H-pyrido(2,3-B) (1,4)benzodiazepin-6-ones and salts thereof |
CH643263A5 (de) * | 1979-05-11 | 1984-05-30 | Sandoz Ag | Benzodiazepine, ihre herstellung und verwendung. |
IL62792A (en) * | 1980-05-07 | 1985-02-28 | Byk Gulden Lomberg Chem Fab | Acylated dihydrothienodiazepinone compounds,process for their preparation,and medicaments containing them |
DE3028001A1 (de) * | 1980-07-24 | 1982-02-18 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue, in 5-stellung substituierte 5,10-dihydro-11h-dibenzo (b,e)(1,4) diazepin-11-one, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel |
DE3262922D1 (en) * | 1981-02-02 | 1985-05-15 | Byk Gulden Lomberg Chem Fab | Tricyclic pyrrols, process for their preparation, their use and compositions containing them |
DE3122670A1 (de) * | 1981-06-06 | 1982-12-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | "neue 1,4,9,10-tetrahydro-pyrazolo(4,3-e) pyrido(3,2-b)(1,4)diazepin-10-one, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von pharmazeutischen wirkstoffen" |
DE3204169A1 (de) * | 1982-02-06 | 1983-08-11 | Dr. Karl Thomae Gmbh, 7950 Biberach | Substituierte thienobenzodiazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
DE3204401A1 (de) * | 1982-02-09 | 1983-08-11 | Dr. Karl Thomae Gmbh, 7950 Biberach | Pyridobenzodiazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
IT1212742B (it) * | 1983-05-17 | 1989-11-30 | Dompe Farmaceutici Spa | Derivati dibenzo [1,4]diazepinonici pirido [1,4] benzodiazepinonici,pirido [1,5] benzodiazepinonici e loro attivita' farmacologica |
DD236731B3 (de) * | 1983-10-19 | 1992-12-10 | Dresden Arzneimittel | Verfahren zur herstellung von neuen in 5-stellung substituierten 5,10-dihydro-11h-dibenzo|b,e¨|1,4¨diazepin-11-onen |
DE3409237A1 (de) * | 1984-03-14 | 1985-09-19 | Dr. Karl Thomae Gmbh, 7950 Biberach | Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
EP0213293B1 (de) * | 1985-06-27 | 1992-01-02 | Dr. Karl Thomae GmbH | In 11-Stellung substituierte 5,11-Dihydro-6H-pyrido-[2,3-b][1,4]benzodiazepin-6-one, Verfahren zur ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
-
1986
- 1986-12-20 DE DE19863643666 patent/DE3643666A1/de not_active Withdrawn
-
1987
- 1987-12-05 AT AT87118030T patent/ATE61367T1/de not_active IP Right Cessation
- 1987-12-05 ES ES87118030T patent/ES2021000B3/es not_active Expired - Lifetime
- 1987-12-05 EP EP87118030A patent/EP0273239B1/de not_active Expired - Lifetime
- 1987-12-05 DE DE8787118030T patent/DE3768457D1/de not_active Expired - Fee Related
- 1987-12-16 PH PH36244A patent/PH25579A/en unknown
- 1987-12-17 PT PT86394A patent/PT86394B/pt not_active IP Right Cessation
- 1987-12-18 US US07/136,212 patent/US4873236A/en not_active Expired - Fee Related
- 1987-12-18 DK DK669187A patent/DK170670B1/da not_active IP Right Cessation
- 1987-12-18 HU HU875864A patent/HU199468B/hu not_active IP Right Cessation
- 1987-12-18 IE IE343687A patent/IE60265B1/en not_active IP Right Cessation
- 1987-12-18 NO NO875318A patent/NO166645C/no unknown
- 1987-12-18 AU AU82806/87A patent/AU596479B2/en not_active Ceased
- 1987-12-18 ZA ZA879492A patent/ZA879492B/xx unknown
- 1987-12-18 NZ NZ222994A patent/NZ222994A/xx unknown
- 1987-12-18 FI FI875583A patent/FI86725C/fi not_active IP Right Cessation
- 1987-12-18 IL IL84874A patent/IL84874A/xx not_active IP Right Cessation
- 1987-12-18 JP JP62321183A patent/JP2574348B2/ja not_active Expired - Lifetime
- 1987-12-18 DD DD87310750A patent/DD275243A5/de not_active IP Right Cessation
- 1987-12-18 CA CA000554792A patent/CA1320197C/en not_active Expired - Fee Related
- 1987-12-19 KR KR1019870014562A patent/KR950014867B1/ko not_active IP Right Cessation
-
1991
- 1991-05-10 GR GR91400597T patent/GR3001933T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4592077B2 (ja) | 嘔吐、抑鬱、不安および咳の処置のためのニューロキニン−1(nk−1)アンタゴニストとしての1−アミド−4−フェニル−4−ベンジルオキシメチル−ピペリジン誘導体および関連化合物 | |
DK171023B1 (da) | Basisk substituerede tricykliske diazepinoner, fremgangsmåde til deres fremstilling og lægemiddel indeholdende sådanne forbindelser | |
TW201105667A (en) | Dihydronaphthyridinyl and related compounds for use in treating ophthalmological disorders | |
MXPA02000978A (es) | Antagonistas del receptor de quimioquina y metodosde uso de los mismos. | |
KR20110015704A (ko) | 정신병성 및 신경퇴행성 장애의 치료를 위한 n-achr의 콜린성 리간드로서의 (1-아자-비시클로[3.3.1]논-4-일)-[5-(1h-인돌-5-일)-헤테로아릴]-아민 | |
AU670981B2 (en) | Tricyclic condensed heterocyclic compounds, their production and use | |
DE69911580T2 (de) | Benzamidderivate als vasopressin-antagonisten | |
US20060234997A1 (en) | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | |
US7141579B2 (en) | Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient | |
WO1999000388A1 (fr) | Nouveaux derives de naphthyridine ou leurs sels | |
DK170670B1 (da) | Kondenserede diazepinoner, fremgangsmåde til deresfremstilling, lægemidler indeholdende en sådan diazepinon, samt anvendelse af sådanne diazepinoner til fremstilling af lægemidler | |
WO2011036885A1 (ja) | 複素環化合物 | |
KR0163413B1 (ko) | 신경이완성 퍼하이드로-1H-피리도[1,2-a] 피라진 | |
DK169722B1 (da) | Substituerede pyrido [2,3-b][1,4]benzodiazepin-6-oner, lægemidler med indhold af forbindelserne, forbindelserne til anvendelse ved behandling af bradycardi og bradyarrhytmi samt fremgangsmåde til fremstilling af forbindelserne | |
CA1321996C (en) | Condensed diazepinones, processes for preparing them and pharmaceutical compositions containing these compounds | |
JP2007533713A (ja) | N−[4−4(4−モルホリニル)フェニル]−[(4−ピペリジニル)メチル]カルボキシアミド誘導体、およびグリシントランスポーター阻害薬としてのその使用 | |
US5002943A (en) | Condensed diazepinones, processes for preparing them and pharmaceutical compositions containing these compounds | |
NO169539B (no) | Analogifremgangsmaate til fremstilling av terapeutisk aktive kondenserte diazepinoner | |
JPH0597845A (ja) | 縮合ジアゼピノン及びこれらの化合物を含む薬剤 | |
NZ229409A (en) | Substituted diazepinones and pharmaceutical compositions | |
NZ229524A (en) | Condensed diazepinones and pharmaceutical compositions | |
NZ229523A (en) | Condensed diazepinones and pharmaceutical compositions thereof | |
JP2007533714A (ja) | N−[6−(4−モルホリニル)−3−ピリジニル]−2−(テトラヒドロ−2h−ピラン−4−イル)−n−[(1−{[フェニル]メチル}−4−ピペリジニル)メチル]アセトアミド誘導体および統合失調症などの精神病を治療するためのglyt1輸送阻害剤としての関連化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B1 | Patent granted (law 1993) | ||
PBP | Patent lapsed |